Ryan M. Bertoli

Ryan M. Bertoli

Auto-generated profile, based on publicly available information

Ryan M. Bertoli

Genetics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland. 1

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 August 2020 in mBio
Verified
Journal Article
Open access
PDF file
CDCynthia L. Darnell
Cynthia L. Darnell
JZJenny Zheng
Jenny Zheng
SWSean Wilson
Sean Wilson
RBRyan M. Bertoli
Ryan M. Bertoli
ABAlexandre Bisson
Alexandre Bisson
ASAmy K Schmid
Amy K Schmid
Healthy cell growth and division are critical for individual organism survival and species long-term viability. However, it remains unknown how cells of the domain Archaea maintain a healthy cell cycle. Understanding the archaeal cell cycle is of paramount evolutionary importance given that an archaeal cell was the host of the endosymbiotic event that gave rise to eukaryotes. Here, we identify and characterize novel molecular players needed for regulating cell division in archaea. These molecules dictate the timing of cell septation but are dispensable for growth between divisions. Timing is accomplished through transcriptional control of the cell division ring. Our results shed light on mechanisms underlying the archaeal cell cycle, which has thus far remained elusive.

4 June 2024 in Cancer Research
Verified
Journal Article
Closed access
PDF file
RBRyan M. Bertoli
Ryan M. Bertoli
YCYang Jo Chung
Yang Jo Chung
MDMichael J. Difilippantonio
Michael J. Difilippantonio
AWAnthony Wokasch
Anthony Wokasch
MMMadison R.B. Marasco
Madison R.B. Marasco
PAPeter D. Aplan
Peter D. Aplan
DNA methyltransferase inhibitors (DNMTi), most commonly cytidine analogs, are compounds that decrease 5′-cytosine methylation. DNMTi are used clinically based on the hypothesis that cytosine demethylation will lead to re-expression of tumor suppressor genes. 5-Aza-4′-thio-2′-deoxycytidine (Aza-TdCyd or ATC) is a recently described thiol-substituted DNMTi that has been shown to have anti-tumor activity in solid tumor models. In this study, we investigated the therapeutic potential of ATC in a murine transplantation model of myelodysplastic syndrome. ATC treatment led to the transformation of transplanted wild-type bone marrow nucleated cells into lymphoid leukemia, and healthy mice treated with ATC also developed lymphoid leukemia. Whole-exome sequencing revealed 1,000 acquired mutations, almost all of which were C>G transversions in a specific 5′-NCG-3′ context. These mutations involved dozens of genes involved in human lymphoid leukemia, such as Notch1, Pten, Pax5, Trp53, and Nf1. Human cells treated in vitro with ATC showed 1,000 acquired C>G transversions in a similar context. Deletion of Dck, the rate-limiting enzyme for the cytidine salvage pathway, eliminated C>G transversions. Taken together, these findings demonstrate a highly penetrant mutagenic and leukemogenic phenotype associated with ATC. Significance: Treatment with a DNA methyltransferase inhibitor generates a distinct mutation signature and triggers leukemic transformation, which has important implications for the research and clinical applications of these inhibitors.

1 August 2024
Verified
Other
Open access
RBRyan M. Bertoli
Ryan M. Bertoli
YCYang Jo Chung
Yang Jo Chung
MDMichael J. Difilippantonio
Michael J. Difilippantonio
AWAnthony Wokasch
Anthony Wokasch
MMMadison R.B. Marasco
Madison R.B. Marasco
PAPeter D. Aplan
Peter D. Aplan
DNA methyltransferase inhibitors (DNMTi), most commonly cytidine analogs, are compounds that decrease 5′-cytosine methylation. DNMTi are used clinically based on the hypothesis that cytosine demethylation will lead to re-expression of tumor suppressor genes. 5-Aza-4′-thio-2′-deoxycytidine (Aza-TdCyd or ATC) is a recently described thiol-substituted DNMTi that has been shown to have anti-tumor activity in solid tumor models. In this study, we investigated the therapeutic potential of ATC in a murine transplantation model of myelodysplastic syndrome. ATC treatment led to the transformation of transplanted wild-type bone marrow nucleated cells into lymphoid leukemia, and healthy mice treated with ATC also developed lymphoid leukemia. Whole-exome sequencing revealed 1,000 acquired mutations, almost all of which were C>G transversions in a specific 5′-NCG-3′ context. These mutations involved dozens of genes involved in human lymphoid leukemia, such as Notch1, Pten, Pax5, Trp53, and Nf1. Human cells treated in vitro with ATC showed 1,000 acquired C>G transversions in a similar context. Deletion of Dck, the rate-limiting enzyme for the cytidine salvage pathway, eliminated C>G transversions. Taken together, these findings demonstrate a highly penetrant mutagenic and leukemogenic phenotype associated with ATC.Significance: Treatment with a DNA methyltransferase inhibitor generates a distinct mutation signature and triggers leukemic transformation, which has important implications for the research and clinical applications of these inhibitors.

1 August 2024
Verified
Other
Open access
RBRyan M. Bertoli
Ryan M. Bertoli
YCYang Jo Chung
Yang Jo Chung
MDMichael J. Difilippantonio
Michael J. Difilippantonio
AWAnthony Wokasch
Anthony Wokasch
MMMadison R.B. Marasco
Madison R.B. Marasco
PAPeter D. Aplan
Peter D. Aplan
Supp_Tables_S1-S13 from The DNA Methyltransferase Inhibitor 5-Aza-4′-thio-2′-Deoxycytidine Induces C>G Transversions and Acute Lymphoid Leukemia Development

1 August 2024
Verified
Other
Open access
RBRyan M. Bertoli
Ryan M. Bertoli
YCYang Jo Chung
Yang Jo Chung
MDMichael J. Difilippantonio
Michael J. Difilippantonio
AWAnthony Wokasch
Anthony Wokasch
MMMadison R.B. Marasco
Madison R.B. Marasco
PAPeter D. Aplan
Peter D. Aplan
DNA methyltransferase inhibitors (DNMTi), most commonly cytidine analogs, are compounds that decrease 5′-cytosine methylation. DNMTi are used clinically based on the hypothesis that cytosine demethylation will lead to re-expression of tumor suppressor genes. 5-Aza-4′-thio-2′-deoxycytidine (Aza-TdCyd or ATC) is a recently described thiol-substituted DNMTi that has been shown to have anti-tumor activity in solid tumor models. In this study, we investigated the therapeutic potential of ATC in a murine transplantation model of myelodysplastic syndrome. ATC treatment led to the transformation of transplanted wild-type bone marrow nucleated cells into lymphoid leukemia, and healthy mice treated with ATC also developed lymphoid leukemia. Whole-exome sequencing revealed 1,000 acquired mutations, almost all of which were C>G transversions in a specific 5′-NCG-3′ context. These mutations involved dozens of genes involved in human lymphoid leukemia, such as Notch1, Pten, Pax5, Trp53, and Nf1. Human cells treated in vitro with ATC showed 1,000 acquired C>G transversions in a similar context. Deletion of Dck, the rate-limiting enzyme for the cytidine salvage pathway, eliminated C>G transversions. Taken together, these findings demonstrate a highly penetrant mutagenic and leukemogenic phenotype associated with ATC.Significance: Treatment with a DNA methyltransferase inhibitor generates a distinct mutation signature and triggers leukemic transformation, which has important implications for the research and clinical applications of these inhibitors.

1 August 2024
Verified
Other
Open access
RBRyan M. Bertoli
Ryan M. Bertoli
YCYang Jo Chung
Yang Jo Chung
MDMichael J. Difilippantonio
Michael J. Difilippantonio
AWAnthony Wokasch
Anthony Wokasch
MMMadison R.B. Marasco
Madison R.B. Marasco
PAPeter D. Aplan
Peter D. Aplan
Supp_Fig_S1-S19 from The DNA Methyltransferase Inhibitor 5-Aza-4′-thio-2′-Deoxycytidine Induces C>G Transversions and Acute Lymphoid Leukemia Development